Huachuang Shenting Completes Pre-A Funding Round, Aims to Lead Non-Invasive Intracranial AI Diagnostics Market
Recently, Huachuang Shenting (Chongqing) Medical Equipment Co., Ltd., a leading domestic R&D enterprise in medical devices, announced the completion of its Pre-A financing round of nearly RMB 10 million. The investor in this round was Shenzhen Tamarace Capital. This milestone marks the company’s entry into a new phase in the field of AI technology for brain health and demonstrates the investor’s strong recognition of its technological innovation capabilities and market potential.
Breakthrough Technologies Empowering Full-Cycle Management of Cranial and Cerebral Health
Huachuang Shenting (Chongqing) Medical Equipment Co., Ltd. specializes in the independent research and development of non-invasive brain health monitoring technologies. Its core product, the Non-Invasive Dynamic Monitor for Cerebral Edema, leverages specific electromagnetic wave detection technology and artificial intelligence algorithms to deliver intelligent solutions covering the entire lifecycle of brain health, thereby enabling dynamic monitoring and early screening of brain diseases. The company’s Chief Scientist, Professor Wu Qi, has received prestigious awards including the Second Prize of the National Science and Technology Progress Award and the First Prize of the Chinese People's Liberation Army Science and Technology Progress Award. The product has undergone five generations of continuous iteration and is widely used in clinical departments such as neurology, neurosurgery, intensive care units (ICU), pediatrics, pediatric intensive care units (PICU), emergency medicine, and geriatrics. Furthermore, it has achieved dual breakthroughs in both technology and application in the early differential diagnosis of stroke and brain health screening for the elderly, filling a global gap in related technologies.
As an innovation leader in the industry, the company has built a globally competitive technical system based on its independently developed AI algorithms and big data platform. With multimodal scalability, it has laid the foundation for future product line deployment:
• Proprietary Core Technologies: From proprietary biosensors to AI algorithm models, all core technologies are independently developed, overcoming the technical bottlenecks of traditional brain health assessment methods.
• Globally Leading Technological Capabilities: The company’s technologies for early disease screening, intelligent monitoring, and early differential diagnosis are at the international leading level, filling a global technological gap.
• Manifestation of New Quality Productive Forces: By integrating innovative technologies with smart healthcare, the company has achieved an efficient closed loop spanning scientific innovation, R&D and manufacturing, to clinical application, significantly raising competitive barriers and enhancing product competitiveness.
Capital Infusion Supports Multidimensional Development
Huachuang Shenting stated that the proceeds from this round of financing will be primarily used for the following purposes:
(1) Technological Breakthroughs and Product Upgrades: Strengthen the construction of the industry-academia-research-medical system, comprehensively advance the research and development of new products, while optimizing the upgrading and iteration of existing products to continuously maintain a global technological leadership position.
(2) Market Expansion and Brand Enhancement: Accelerate market coverage across hospitals at all levels in China, further deepen market penetration in primary healthcare institutions, and simultaneously explore market access and promotion in international markets.
(3) Intelligent Manufacturing and the Development of New Quality Productive Forces: By introducing intelligent manufacturing systems, optimize production line efficiency and quality to fully prepare for large-scale market demand.
(4) Building Top-Tier Teams: Attract top talent in the fields of AI, chip technology, sensor technology, IoT technology, and the healthcare market to provide greater support for the company’s technological innovation and business expansion.
Investor Perspective: Bullish on Dual Drivers of Technology and Market
Zhou Yanjin (Yan), Partner at Tamarace Capitalstated: “Huachuang Shenting has demonstrated strong innovation capabilities and market potential in the field of AI-based cranial detection. Its non-invasive, digitalized biological tissue testing system, along with its consumables-based business model, not only enjoys robust demand in the domestic market but also holds significant room for expansion internationally. We believe that, driven by both the team’s execution capability and technological expertise, the company will rapidly grow into a leading enterprise in this sector.”
Industry Outlook and Corporate Vision
With the intensifying aging of the population and rising health awareness, brain health management has gradually become a key focus in the healthcare industry. The cranial diagnostic equipment market is projected to achieve a compound annual growth rate (CAGR) of over 25% in the next five years, presenting significant opportunities for technology-driven enterprises.
Huachuang Shenting (Chongqing) Medical Equipment Co., Ltd. stated that it will continue to deepen its expertise in non-invasive cranial condition monitoring technology, driving technological upgrades within the industry and advancing the substitution of imported products with domestically produced alternatives. Meanwhile, the company will actively fulfill its social responsibilities by enhancing the accessibility of medical services through technological innovation, thereby contributing to the national cause of public health.